Total Payments
$56,227
2024 Payments
$3,201
Companies
16
Transactions
108
Medicare Patients
1,249
Medicare Billing
$221,668
Payment Breakdown by Category
Consulting$37,738 (67.1%)
Other$13,636 (24.3%)
Travel$2,404 (4.3%)
Food & Beverage$1,463 (2.6%)
Education$508.43 (0.9%)
Research$477.77 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,738 | 10 | 67.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,245 | 2 | 14.7% |
| Honoraria | $5,391 | 3 | 9.6% |
| Travel and Lodging | $2,404 | 9 | 4.3% |
| Food and Beverage | $1,463 | 30 | 2.6% |
| Education | $508.43 | 53 | 0.9% |
| Unspecified | $477.77 | 1 | 0.8% |
Payments by Type
General
$55,749
107 transactions
Research
$477.77
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $23,786 | 29 | $0 (2024) |
| PFIZER INC. | $12,815 | 55 | $0 (2020) |
| Blueprint Medicines Corporation | $5,391 | 3 | $0 (2022) |
| AbbVie, Inc. | $4,051 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $3,308 | 2 | $0 (2018) |
| Roche Diagnostics Corporation | $3,132 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,808 | 2 | $0 (2020) |
| F. Hoffmann-La Roche AG | $477.77 | 1 | $0 (2020) |
| Lilly USA, LLC | $160.29 | 2 | $0 (2019) |
| Genentech USA, Inc. | $144.71 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,201 | 4 | Roche Diagnostics Corporation ($3,132) |
| 2023 | $100.80 | 4 | AstraZeneca Pharmaceuticals LP ($37.45) |
| 2022 | $2,772 | 1 | Blueprint Medicines Corporation ($2,772) |
| 2021 | $2,025 | 1 | Blueprint Medicines Corporation ($2,025) |
| 2020 | $27,612 | 13 | PFIZER INC. ($12,386) |
| 2019 | $5,123 | 36 | AstraZeneca Pharmaceuticals LP ($4,426) |
| 2018 | $3,525 | 20 | E.R. Squibb & Sons, L.L.C. ($3,308) |
| 2017 | $11,868 | 29 | AstraZeneca Pharmaceuticals LP ($7,635) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: BioOncology | ||||||
| 08/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $3,132.00 | General |
| Category: None | ||||||
| 05/17/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $32.96 | General |
| Category: Oncology | ||||||
| 12/15/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $37.45 | General |
| 07/21/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 07/04/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: SURGERY | ||||||
| 05/10/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $17.41 | General |
| Category: Oncology | ||||||
| 03/25/2022 | Blueprint Medicines Corporation | GAVRETO (Drug) | Honoraria | Cash or cash equivalent | $2,772.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 02/04/2021 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $2,025.00 | General |
| 11/13/2020 | PFIZER INC. | XALKORI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,205.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,440.00 | General |
| 09/09/2020 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $593.75 | General |
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $477.77 | Research |
| Study: A phase III, open-label, randomized study of MPDL3280A anti-PDL-1 antibody in combination with carboplatin paclitaxel with or without Bevacizumab compared with carboplatin paclitaxel bevacizumab in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer • Category: BioOncology | ||||||
| 04/11/2020 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2020 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,040.00 | General |
| 03/09/2020 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.76 | General |
| Category: ONCOLOGY | ||||||
| 02/03/2020 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $3,545.00 | General |
| Category: ONCOLOGY | ||||||
| 01/20/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,550.00 | General |
| 01/20/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 01/10/2020 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $446.96 | General |
| 01/10/2020 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $74.13 | General |
| 01/10/2020 | PFIZER INC. | XALKORI (Drug) | Food and Beverage | In-kind items and services | $64.86 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2019 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $10.34 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $456.83 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase III, open-label, randomized study of MPDL3280A anti-PDL-1 antibody in combination with carboplatin paclitaxel with or without Bevacizumab compared with carboplatin paclitaxel bevacizumab in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer | F. Hoffmann-La Roche AG | $477.77 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 160 | 278 | $77,572 | $20,975 |
| 2022 | 6 | 361 | 811 | $236,832 | $71,423 |
| 2021 | 6 | 367 | 780 | $220,511 | $65,938 |
| 2020 | 7 | 361 | 820 | $238,373 | $63,332 |
Total Patients
1,249
Total Services
2,689
Medicare Billing
$221,668
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 183 | $57,462 | $15,374 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 65 | $13,780 | $3,939 | 28.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 30 | $6,330 | $1,661 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 133 | 458 | $143,812 | $45,060 | 31.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 105 | 163 | $34,556 | $11,074 | 32.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $21,735 | $5,674 | 26.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 43 | 95 | $20,045 | $5,323 | 26.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 34 | $10,268 | $2,653 | 25.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 16 | $6,416 | $1,639 | 25.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 365 | $114,610 | $35,903 | 31.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 66 | 165 | $34,815 | $9,377 | 26.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 90 | 131 | $27,772 | $9,102 | 32.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 71 | $21,442 | $5,730 | 26.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $15,456 | $4,125 | 26.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 16 | 16 | $6,416 | $1,700 | 26.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 142 | 467 | $146,638 | $38,402 | 26.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 94 | 129 | $27,348 | $7,262 | 26.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 109 | $22,999 | $6,494 | 28.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 60 | $18,120 | $5,001 | 27.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 24 | 24 | $11,592 | $2,931 | 25.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 17 | 20 | $8,420 | $2,314 | 27.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 11 | 11 | $3,256 | $928.69 | 28.5% |
About Dr. Eric Bernicker, MD
Dr. Eric Bernicker, MD is a Medical Oncology healthcare provider based in Longmont, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316924806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Bernicker, MD has received a total of $56,227 in payments from pharmaceutical and medical device companies, with $3,201 received in 2024. These payments were reported across 108 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($37,738).
As a Medicare-enrolled provider, Bernicker has provided services to 1,249 Medicare beneficiaries, totaling 2,689 services with total Medicare billing of $221,668. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Longmont, CO
- Active Since 12/27/2005
- Last Updated 03/07/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1316924806
Products in Payments
- IMFINZI (Drug) $7,573
- XALKORI (Drug) $5,815
- TAGRISSO (Drug) $3,399
- OPDIVO (Biological) $3,308
- GAVRETO (Drug) $2,772
- TABRECTA (Drug) $2,500
- Tecentriq (Biological) $477.77
- IBRANCE (Drug) $416.96
- Avastin (Biological) $126.78
- ALIMTA (Drug) $83.95
- CYRAMZA (Drug) $76.34
- GILOTRIF (Drug) $49.56
- Da Vinci Surgical System (Device) $26.13
- TALZENNA (Drug) $22.10
- Corlanor (Drug) $21.96
- KEYTRUDA (Biological) $19.81
- Enhertu (Drug) $18.30
- Kadcyla (Biological) $17.93
- CABOMETYX (Drug) $17.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.